Stay updated on Reslizumab in EGPA: Clinical Trial
Sign up to get notified when there's something new on the Reslizumab in EGPA: Clinical Trial page.

Latest updates to the Reslizumab in EGPA: Clinical Trial page
- Check5 days agoChange DetectedThe page has been updated to reflect a new version of the study, with the addition of collaborators and a specific study location, while significant details about the study drug, reslizumab, have been removed.SummaryDifference36%
- Check12 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check19 days agoNo Change Detected
- Check27 days agoNo Change Detected
- Check56 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check71 days agoChange DetectedThe webpage now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check78 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check92 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
Stay in the know with updates to Reslizumab in EGPA: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Reslizumab in EGPA: Clinical Trial page.